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Diabetic foot ulcers (DFUs) are a serious complication of diabetes. Previous exposure to hyperglycemic conditions
accelerates a decline in cellular function through metabolic memory despite normalization of glycemic control.
Persistent, hyperglycemia-induced epigenetic patterns are considered a central mechanism that activates metabolic
memory; however, this has not been investigated in patient-derived ﬁbroblasts from DFUs. We generated a cohort of
patient-derived lines from DFU ﬁbroblasts (DFUF), and site- and age-matched diabetic foot ﬁbroblasts (DFF) and non-
diabetic foot ﬁbroblasts (NFF) to investigate global and genome-wide DNA methylation patterns using liquid
chromatography/mass spectrometry and the Illumina Inﬁnium HumanMethylation450K array. DFFs and DFUFs
demonstrated signiﬁcantly lower global DNA methylation compared to NFFs (p D 0.03). Hierarchical clustering of
differentially methylated probes (DMPs, p D 0.05) showed that DFFs and DFUFs cluster together and separately from
NFFs. Twenty-ﬁve percent of the same probes were identiﬁed as DMPs when individually comparing DFF and DFUF to
NFF. Functional annotation identiﬁed enrichment of DMPs associated with genes critical to wound repair, including
angiogenesis (p D 0.07) and extracellular matrix assembly (p D 0.035). Identiﬁcation of sustained DNA methylation
patterns in patient-derived ﬁbroblasts after prolonged passage in normoglycemic conditions demonstrates persistent
metabolic memory. These ﬁndings suggest that epigenetic-related metabolic memory may also underlie differences in
wound healing phenotypes and can potentially identify therapeutic targets.
Introduction
A constellation of disease complications arise from chronic
hyperglycemia and associated low-grade inflammation, contrib-
uting to the morbidity and mortality of diabetes. There is strong
epidemiological evidence that previous exposure to hyperglyce-
mia drives the progression of diabetic complications through a
mechanism called “metabolic memory.”1 Metabolic memory in
diabetes is defined as a persistent decline in cellular function in
response to previous exposure to hyperglycemia despite normali-
zation of glycemic control.1,2 This was well established by the
Diabetes Control and Complications Trial (DCCT), where sub-
jects treated with intensive insulin therapy for many years main-
tained superior glycemic control and developed fewer diabetic
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complications. The persistence of these outcomes was identified
in the observational Epidemiology of Diabetes Interventions and
Complications (EDIC) follow-up trial, in which all subjects
from DCCT were treated with long-term, intensive insulin ther-
apy.3 Subjects demonstrated indistinguishable hemoglobin A1c
(HbA1c) levels; however, individuals initially treated with con-
ventional insulin therapy displayed accelerated progression of
diabetic complications, including hypertension, retinopathy,
neuropathy, and microvascular complications, such as nephropa-
thy.4,5 These findings, which have been further substantiated at
the 20-year follow up EDIC reports,3 demonstrate the impact of
persistent metabolic memory and the urgent need for strict glu-
coregulatory control in the management of diabetic patients.
It is now well established that a central mechanism underlying
metabolic memory is the persistence of hyperglycemia-associated
epigenetic patterns that sustain and drive the progression of dis-
ease phenotypes, despite long-term normalization of glycemic
control. Unlike other molecular markers of diabetic status, such
as the presence of glycated proteins, heritable transmission of epi-
genetic patterns across mitotic cell division can maintain hyper-
glycemia-driven epigenetic patterns despite removal of the
glycemic insult.6,7 This metabolic memory has been demon-
strated at the level of genome-wide DNA methylation,8,9 defined
histone modifications,6,8,10,11 microRNA expression patterns12,13
and specific modulation of epigenetic regulatory machinery in
animal and human studies12 across a range of diabetes-relevant
tissues, including retinal, renal and vascular cells.2 Collectively,
these studies have demonstrated gene expression and epigenetic
profiles that are enriched in diabetes-relevant pathways, including
metabolism and inflammation, and correlated with impaired
cellular function and clinical complications. While a role for
metabolic memory in diabetic complications has been studied in
numerous cell types, including vascular smooth muscle cells,6,12
endothelial cells,8 glomerular mesangial cells,10 and retinal
cells,11 no previous studies14 have focused on the role of epige-
netic metabolic memory in establishing a diabetic phenotype spe-
cifically in fibroblasts derived from chronic, non-healing diabetic
foot ulcers (DFUs).
Diabetic foot ulceration is a serious complication that signifi-
cantly impairs the quality of patient life. Existing therapies, such
as growth factor treatment15 and bioactive dressings harboring
na€ıve fibroblasts that do not integrate into host tissues,16-18 have
high failure rates and require repeated applications.17,18 Further-
more, there is limited understanding as to which diabetic patients
are susceptible to the development of chronic, non-healing
DFUs19 and why DFU treatments are effective in some patients
and not in others. This lack of response to therapy demonstrates
the urgent need to develop new insights into the risk profile of
diabetic patients who may develop these complications in ways
that can lead to next generation treatments for these chronic
wounds.
As a mediator of crosstalk between multiple cell types critical
to normal wound repair, fibroblasts are an essential cell type
in wound healing due to their production of extracellular
matrix (ECM), secretion of cytokines, support of re-epithelializa-
tion, and activation of angiogenesis.20 Previous studies have
demonstrated that fibroblasts are altered in many types of chronic
wounds,21,22 but their role in initiating and maintaining the non-
healing, diabetic environment remains unclear.23,24 In particular,
the epigenetic profile associated with metabolic memory in fibro-
blasts resident in diabetic ulcers or in patients at risk for develop-
ing them has not been studied and may reveal new targets that
underlie compromised tissue regeneration and repair. To date,
there are no studies that have characterized the epigenetic profile
of a large human cohort of fibroblasts derived from DFUs when
compared to site-, age-, and disease-matched, and normal-
matched fibroblasts.
The aim of our current study was to characterize the DNA
methylation signature of diabetic fibroblasts harvested directly
from diabetic wounds and diabetic patients to determine whether
the diabetic microenvironment alters epigenetic patterns. Differ-
ences in DNA methylation detected after prolonged culture of
these diabetic, patient-derived fibroblast cell lines in normoglyce-
mic conditions strongly suggest retained metabolic memory that
is associated with poor wound healing outcomes in these diabetic
patients.
Results
Generation of patient-derived cell lines
We generated a cohort of 12 patient-derived foot fibroblast
cell lines from 3 groups of study participants including (1) Dia-
betic Foot Ulcer Fibroblasts (DFUF), (2) Diabetic Foot Fibro-
blasts (DFF) from diabetic patients without foot ulcers, and (3)
Non-diabetic Foot Fibroblasts (NFF) from non-diabetic subjects
without foot ulcers. The subject demographics and biopsy char-
acteristics of the 4 patient-derived cell lines per group are pre-
sented in Table 1. No significant differences in age or gender
were observed between patient groups. Mean diabetes duration,
blood glucose, and hemoglobin A1c are presented per group.
Global DNA methylation
To gain a top-down view of global epigenomic patterns, we
first investigated global DNA methylation by liquid chromatog-
raphy/mass spectrometry (LC/MS). Both DFF and DFUF sam-
ples displayed significantly lower percent DNA methylation
compared to NFF (mean difference ¡0.32%; p D 0.03; Fig. 1).
We observed a trend for lower percent DNA methylation in
DFUF compared to DFF, though differences were not significant
(p > 0 .05). This demonstrates that there are substantive changes
in global DNA methylation in response to diabetes, suggesting
major alterations in genomic integrity and gene expression.
Genome-wide DNA methylation array
Three 2-group contrasts were performed with the data, com-
paring DFUF vs. NFF, DFF vs. NFF, and DFUF vs. DFF (Sup-
plementary Table). One 3-group contrast was performed
comparing DFUF, DFF, and NFF to each other. All 2-group
contrasts identified a similar number of differentially methylated
probes (DMPs), range 172–190, and 375 DMPs were identified
in the 3-group comparison (Fig. 2a). Hierarchical clustering
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analysis of DMPs in the 3-group comparison demonstrated that
DFUFs and DFFs cluster together and separately from NFFs,
visualized as a heat map (Fig. 2b). Comparison of all the DMPs
identified in the 3 2-group contrasts demonstrated that DFUF
vs. NFF and DFF vs. NFF identified 45 of the same sites as being
differentially methylated, which represents 25% of all the DMPs
identified in these contrasts (Fig. 2c). Shared diabetic DMPs
demonstrated a similar methylation b value in DFFs and DFUFs
[mean absolute (bDFF-bDFUF) of 0.122, SD D 0.099] with
the same direction of difference compared to NFFs (Table 2).
Taken together, these observations support that we have identi-
fied a consistent diabetic epigenotype in foot-derived fibroblasts,
regardless of patient ulcer status. Three probes were identified to
be differentially methylated across all 3 contrasts; however, there
was no consistent pattern in the direction of methylation differ-
ences between the groups or evident biological relevance of the
associated genes in our context (Supplementary Table).
Characterization of shared diabetic DMPs
Annotation of common diabetic DMPs to genomic regions
identified that differential methylation was localized to both
proximal and distal gene regions, with the greatest number of
DMPs within gene bodies and DHSs (Fig. 3a). Due to the com-
plicated nature of genome structure, one individual probe site
may fit the criteria of several genomic region categories. Overlap
between our diabetic DMP sites and histone modification peaks
identified in Normal Human Lung Fibroblast (NHLF) ChIP-seq
ENCODE data was explored through EpiExplorer and demon-
strated substantial association with activating histone marks
H3K4me1/2/3, H3K9ac, and H3K27ac compared to the ran-
domly generated control data set (Fig. 3b). This suggested that
our diabetic differential methylation may be associated with sites
of active gene expression.
We explored overlap between our diabetic DMPs and TFBS
identified across multiple cell types in the ENCODE dataset
(Fig. 3c). Evidence is surmounting that DNA methylation can
modify the binding affinity of transcription factors to DNA to
fine-tune gene expression regulation.25 Although further confir-
mation would be required in our samples for appropriate tissue
and biological context, this analysis identified localization of dia-
betic DMPs to TFBSs of transcription factors that are known to
regulate gene expression programs relevant to diabetes and
wound healing, namely MAX, Sp1, and YY1.
We used a 2-pronged approach to associate our diabetic
DMPs with genes to generate our list presented in Table 2.
First, we used a proximal approach in which a DMP is asso-
ciated with a gene if it falls within 1500bp upstream of the
TSS through to the 3’UTR. Second, we employed a distal
approach in which a DMP is associated with a gene if it falls
within a DHS that is associated with expression changes of
that gene. This gene annotation method enabled us to esti-
mate gene associations based on both proximity and public
data repositories.
Using the gene list presented in Table 2, we performed further
bioinformatics analyses to gain biological insight into common
Figure 1. Diabetes is associated with lower global DNA methylation.
Regardless of ulcer status, diabetic ﬁbroblasts demonstrate signiﬁcantly
lower DNA methylation compared to non-diabetic ﬁbroblasts (p D 0.03,
mean difference¡0.32%) by 2-way ANOVA for diabetes and ulcer status.
Table 1 – Clinical characteristics
Cell line Age Sex Diabetes Specimen origin Neuropathy Blood glucose (mg/dl) HbA1c (%, mmol/mol) Diabetes duration (yrs)
DFUF1 52 M Type 2 Plantar – ulcer Y 197C/¡88.7 7.7C/¡1.6, 61C/¡18 14.3C/¡1.2,
DFUF2 59 F Type 2 Plantar – ulcer Y
DFUF3 50 M Type 2 2nd metatarsal head – ulcer Y
DFUF4 52 F Type 2 Ankle – ulcer N
DFF5 50 M Type 2 R 5th toe Y 129C/¡23.8 7.0C/¡0.72, 53C/¡8.2 2.29C/¡2.4
DFF6 49 M Type 2 2nd digit Y
DFF7 67 M Type 2 2nd digit Y
DFF8 68 F Type 2 2nd digit Y
NFF9 57 F NA Hammertoe N 90C/¡49 5.4C/¡0.28, 36C/¡3.5 NA
NFF10 39 F NA R foot excision cyst N
NFF11 67 M NA 5th digit N
NFF12 63 F NA 3rd and 4th digit N
Donor characteristics of primary foot ﬁbroblast cell lines. Primary foot ﬁbroblast cell lines were derived from non-diabetic subjects, diabetic subjects with
foot ulcers and diabetic subjects without foot ulcers. No differences in age or sex were observed between the 3 groups. We did not statistically compare
blood glucose, HbA1c, or diabetes duration between groups because we did not have complete data of these parameters for all subjects, with 10 subjects’
blood glucose measures, 8 subjects’ HbA1c measures and 5 diabetic subjects’ disease duration data, therefore we present only summary statistics for these
parameters. DFUF D diabetic foot ulcer ﬁbroblast, DFF D diabetic foot ﬁbroblast, NFF D non-diabetic foot ﬁbroblast.
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diabetic differential methylation. Our DAVID functional anno-
tation clustering identified 3 clusters that may offer biological
insight with enrichment of genes related to oxidation/reduction,
myofibril function and angiogenesis/extracellular matrix func-
tions (Table 3).
To gain additional insight into our genes associated with dia-
betic differential methylation, we uploaded our list into Ingenu-
ity Pathway Analysis (IPA) to explore whether it generates any
interaction networks, deemed significant if the negative log p
value of the Fisher exact test is greater than 2. We identified a
network titled “cell to cell signaling and interaction, tissue devel-
opment, cancer” with a significant score of 8, displaying an inter-
action network with wound-healing relevant nodes including
TGFb, Myc, and TNFa (Fig. 4).
Discussion
In this study we have identified a diabetic epigenotype using a
cohort of 12 patient-derived cell lines, including diabetic foot
ulcer fibroblasts (DFUF), which demonstrate characteristic
features of metabolic memory
based on their persistent expres-
sion of a diabetic phenotype
upon prolonged cell culture.
We have used a cohort of 12
fibroblast derived cell lines,
including 8 cell lines from dia-
betic patients. Previous investi-
gations of fibroblast cell lines
from chronic wounds have
been limited by using only a
small number of fibroblast cell
lines, and most of these studies
have studied fibroblasts from
venous ulcers and not from dia-
betic foot ulcers (DFUs).26-28
This is because fibroblasts
from DFUs have been difficult
to culture, as they have shown
both an impaired responsive-
ness to growth factors and ele-
vated numbers of senescent
cells.29 Thus, we report one of
the largest cohorts of fibroblasts
from diabetic patients that are
site-matched, to healthy control
fibroblasts. This is the first
report of a comprehensive
DNA methylation analysis at
the global and genome-wide
levels using patient-derived
fibroblasts within the context of
diabetic wound healing. Identi-
fication of a persistent diabetic
wound healing-related epigeno-
type in a cohort of patient fibroblasts contributes to a growing lit-
erature demonstrating that epigenetically-driven, metabolic
memory directs cellular phenotypes that lead to complications
associated with diabetes,1,2,6,8,9,14,30 adding further urgency to
the need for strict glycemic control in diabetic therapy.
In order to further our understanding of foot ulcer develop-
ment and wound repair incompetency in diabetic patients who
may be at risk for their development, mechanisms underlying cel-
lular alterations both before and after DFU development are
needed. While our understanding of the pathophysiology of neu-
ropathy and ischemia leading to DFUs has increased in recent
years,31-33 insights into underlying alterations in fibroblasts in
the chronic wound environment in general, and their participa-
tion in metabolic memory in particular, require further study.
One of the challenges in the treatment of DFUs is the unpredict-
able variability in patient response to therapy, leading to treat-
ment failures and limb amputation.19,34 This is partially due to
limitations linked to the isolation and growth of fibroblasts in
primary culture that has complicated their study in vitro. For
example, while numerous studies have examined the behavior of
primary fibroblasts derived from chronic wounds,26–28 fibroblasts
2A.
2B.
2C.
Figure 2. Diabetic ﬁbroblasts demonstrate similar DNA methylation patterns. Differentially methylated
probes (DMPs) identiﬁed in a 3-group comparison and each 2-group comparison (A). Overall, DFFs and DFUFs
cluster together and separately from NFFs based on Euclidean hierarchical clustering of DMPs identiﬁed in the
all-group analysis (B). Of the DMPs identiﬁed in the 2-group contrasts, 25% of DFF vs. NFF and DFUF vs. NFF
identiﬁed differential methylation at the same probe (C).
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from DFUs exhibit a spectrum of biological properties that are
dependent on their site of origin within the wound.29 This het-
erogeneity is further complicated by the fact that fibroblasts iso-
lated and cultured from the superficial dermis contain varied
subpopulations that each have distinct phenotypes and prolifera-
tion kinetics.35 In spite of this, our findings extend previous stud-
ies on chronic wound fibroblasts26–28 by showing that DFU- and
DFF-derived fibroblasts maintain their distinct phenotype and
epigenetic profile in culture. Previous human studies investigat-
ing the role of fibroblasts in DFUs have primarily used
immortalized cell lines following extensive passaging isolated
from tissues that are not from the dermal foot region,36-39 which
are less predictive of in vivo patient outcomes. It has previously
been shown that tissue and context specificity is critical when
studying epigenetic profiles because patterns have been shown to
vary greatly in the same cell type between different tissue micro-
environments,40,41 emphasizing the need to evaluate epigenetic
patterns in cells derived from context-relevant tissues. By profil-
ing epigenetic signatures using well-characterized, patient-derived
fibroblasts, we have found evidence that these cell lines have
Table 2. Annotation of common diabetic DMPs
Probe Gene Location p value NFFb DFFb DFUFb
cg00945409 ZMIZ1 (¡91127); RPS24 (C944148) chr10:80737665 0.057 0.81 C/¡0.08 0.57 C/¡0.21 0.45, C/¡0.25
cg01230320 NT5C1B¡RDH14 (¡779135); OSR1 (C8392) chr2:19549980 0.057 0.92 C/¡0.18 0.56 C/¡0.16 0.59 C/¡0.16
cg01632562 SUPT3H (¡284090); CLIC5 (C418326) chr6:45629759 0.057 0.5 C/¡0.12 0.23 C/¡0.08 0.28 C/¡0.09
cg02100397 FGF22 (C6965); RNF126 (C16343) chr19:646890 0.057 0.88 C/¡0.15 0.3C/¡0.26 0.53 C/¡0.32
cg02138953 PLAU (¡4583) chr10:75666279 0.057 0.65 C/¡0.03 0.41 C/¡0.14 0.35 C/¡0.20
cg02368820 ARHGEF16 (¡318646); PRDM16 (C66760) chr1:3052501 0.057 0.27 C/¡0.29 0.71 C/¡0.05 0.66 C/¡0.14
cg02799905 NRP2 (¡204998); PARD3B (C931711) chr2:206342226 0.057 0.68 C/¡0.12 0.43 C/¡0.15 0.45 C/¡0.15
cg03217995 HOXA7 (¡7135); HOXA9 (C1719) chr7:27203430 0.057 0.36 C/¡0.05 0.56 C/¡0.13 0.58 C/¡0.12
cg03301058 GABRR1 (¡80361); GABRR2 (C17111) chr6:90007856 0.057 0.6 C/¡0.17 0.35 C/¡0.11 0.34 C/¡0.18
cg03859028 TTC23 (¡159475); MEF2A (¡156844) chr15:99949289 0.057 0.17 C/¡0.11 0.42 C/¡0.02 0.4 C/¡0.10
cg04478875 SPRY4 (¡319155); FGF1 (C41879) chr5:142023774 0.057 0.68 C/¡0.04 0.34 C/¡0.07 0.4 C/¡0.12
cg04500819 GORAB (¡124288); METTL11B (C261788) chr1:170376975 0.057 0.81 C/¡0.03 0.56 C/¡0.17 0.5 C/¡0.13
cg04888234 FCRLA (¡1183) chr1:161675579 0.057 0.85 C/¡0.18 0.49 C/¡0.18 0.48 C/¡0.03
cg05949913 CTGF (¡285040); MOXD1 (C165107) chr6:132557557 0.057 0.65 C/¡0.09 0.38 C/¡0.10 0.42 C/¡0.1
cg06486129 C21orf33 (C19917); ICOSLG (C87424) chr21:45573410 0.057 0.14 C/¡0.05 0.43 C/¡0.10 0.36 C/¡0.11
cg06766860 GALNT9 (C41922); NOC4L (C234991) chr12:132863983 0.057 0.44 C/¡0.28 0.74 C/¡0.04 0.66 C/¡0.19
cg07891658 ZNF469 (¡497148); BANP (C11694) chr16:87996731 0.057 0.27 C/¡0.03 0.48 C/¡0.15 0.55 C/¡0.20
cg08797704 CDH5 (¡707920); CDH11 (¡536687) chr16:65692605 0.057 0.45 C/¡0.08 0.2C/¡0.09 0.16 C/¡0.02
cg09259081 KIAA1609 (¡602) chr16:84538889 0.057 0.32 C/¡0.05 0.53 C/¡0.14 0.55 C/¡0.11
cg10270430 MLN (¡252570); GRM4 (C77274) chr6:34024362 0.057 0.19 C/¡0.05 0.4C/¡0.10 0.4 C/¡0.09
cg10590622 PDHA2 (¡294) chr4:96760945 0.057 0.61 C/¡0.24 0.15 C/¡0.01 0.14 C/¡0.19
cg10776061 MAN2B1 (C9201); ZNF791 (C46659) chr19:12768390 0.057 0.54 C/¡0.14 0.3C/¡0.25 0.29 C/¡0.23
cg11728145 PXDN (C90101); TPO (C240958) chr2:1658190 0.057 0.72 C/¡0.08 0.44 C/¡0.20 0.43 C/¡0.22
cg12214399 SPATA18 (C293068); USP46 (C314842) chr4:53210660 0.057 0.14 C/¡0.24 0.59 C/¡0.12 0.55 C/¡0.21
cg13205848 NTF3 (C134226); ANO2 (C379893) chr12:5675505 0.057 0.75 C/¡0.03 0.51 C/¡0.13 0.52 C/¡0.19
cg14223671 GNG13 (¡7249); LMF1 (C163003) chr16:857981 0.057 0.08 C/¡0.08 0.3C/¡0.16 0.29 C/¡0.09
cg14447606 CYP26B1 (C4635); DYSF (C676497) chr2:72370328 0.057 0.11 C/¡0.01 0.32 C/¡0.14 0.44 C/¡0.20
cg14646613 KLF4 (¡160662) chr9:110412708 0.057 0.79 C¡0.06 0.49 C/¡0.24 0.39 C/¡0.18
cg14895374 HMBOX1 (C182571); KIF13B (C190129) chr8:28930481 0.057 0.71 C/¡0.06 0.49 C/¡0.22 0.42 C/¡0.11
cg15752756 HLA¡DQB1 (¡16) chr6:32634481 0.057 0.45 C/¡0.05 0.23 C/¡0.04 0.17 C/¡0.05
cg16112880 TMEM9 (¡114) chr1:201123745 0.057 0.14 C/¡0.02 0.42 C/¡0.32 0.67 C/¡0.14
cg17013691 TRIO (C236495); ANKH (C491564) chr5:14380323 0.057 0.83 C/¡0.13 0.55 C/¡0.02 0.62 C/¡0.11
cg18004235 OSR1 (¡249959); TTC32 (C293414) chr2:19808330 0.057 0.73 C/¡0.12 0.48 C/¡0.05 0.49 C/¡0.17
cg20321086 CLVS1 (¡148318); CHD7 (C460884) chr8:62052207 0.057 0.47 C/¡0.14 0.23 C/¡0.03 0.25 C/¡0.02
cg20895691 ATAD2B (C508386) chr2:23641550 0.057 0.55 C/¡0.08 0.32 C/¡0.09 0.26 C/¡0.10
cg23763647 AKR1E2 (C289) chr10:4868690 0.057 0.29 C/¡0.20 0.07 C/¡0.03 0.05 C/¡0.01
cg24284539 CCDC3 (C44105); CAMK1D (C608017) chr10:12999599 0.057 0.74 C/¡0.07 0.45 C/¡0.26 0.47 C/¡0.24
cg25570222 SIX2 (¡568090); SRBD1 (C33802) chr2:45804631 0.057 0.66 C/¡0.13 0.88 C/¡0.04 0.91 C/¡0.08
cg25638870 NOX4 (¡65) chr11:89224717 0.057 0.18 C/¡0.14 0.43 C/¡0.12 0.42 C/¡0.02
cg27333018 ZNF57 (¡3382) chr19:2897514 0.057 0.69 C/¡0.11 0.48 C/¡0.05 0.47 C/¡0.04
cg00945409 ZMIZ1 (¡91127); RPS24 (C944148) chr10:80737665 0.057 0.81 C/¡0.08 0.57 C/¡0.21 0.45, C/¡0.25
cg01230320 NT5C1B¡RDH14 (¡779135); OSR1 (C8392) chr2:19549980 0.057 0.92 C/¡0.18 0.56 C/¡0.16 0.59 C/¡0.16
cg01632562 SUPT3H (¡284090); CLIC5 (C418326) chr6:45629759 0.057 0.5 C/¡0.12 0.23 C/¡0.08 0.28 C/¡0.09
cg02100397 FGF22 (C6965); RNF126 (C16343) chr19:646890 0.057 0.88 C/¡0.15 0.3C/¡0.26 0.53 C/¡0.32
cg02138953 PLAU (¡4583) chr10:75666279 0.057 0.65 C/¡0.03 0.41 C/¡0.14 0.35 C/¡0.20
Shared DMPs have a similar methylation status between diabetic ﬁbroblasts. Each DMP that was common to both DFF vs NFF and DFUF vs NFF are listed
with their Illumina CpG identiﬁer, probe chromosomal location, gene associations and CpG island relation. All 2 group comparisons that yielded the com-
mon diabetic DMPs had p values of 0.057. Mean b values per group, which reﬂect the methylation status, are listed for DFUF, DFF and NFF demonstrating
similar methylation values for diabetic ﬁbroblasts compared to non-diabetic ﬁbroblasts.
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biological relevance to their in vivo, biological microenvironment
and offer opportunities to gain insights into mechanisms predis-
posing diabetic patients to the development of chronic foot
ulcers. This supports the utility of primary fibroblast cultures as a
tool to study chronic wound pathogenesis and to test potential
therapeutic agents.
This is the first report of epigenetic metabolic memory in a
cohort of patient-derived fibroblast cell lines derived from DFUs.
In our study, DFFs and DFUFs were derived from diabetic
patients with hyperglycemia and subsequently cultured through
4 passages in normoglycemic conditions. Therefore, the diabetic
epigenotype that we have identified represents a hyperglycemia-
associated DNA methylation pattern that is persistent despite
multiple cell culture passages under normoglycemic conditions.
Our finding that the diabetic epigenotype we identified was asso-
ciated with hyperglycemia is supported by previous studies show-
ing persistent epigenetic changes in endothelial cells from
diabetic patients.42 This builds upon previous observations in
animal studies performed with vascular smooth muscle cells
derived from diabetic mice showing maintenance of altered his-
tone modification patterns following ex vivo culturing in normo-
glycemic conditions.6 Zebrafish models of diabetic wound
healing have demonstrated persistent, hyperglycemia-induced
gene expression and DNA
methylation patterns that are
associated with impaired heal-
ing and tissue regeneration in
response to a wounding
insult.9,30 Previous studies in
monozygotic twins (MZ) dis-
cordant for Type 1 diabetes
have demonstrated differences
in gene expression profiles in
dermal fibroblasts,7 which has
been attributed to hyperglyce-
mia-driven epigenetic patterns;
however, this was not investi-
gated directly at the epigenetic
level. Our study extends the
identification of epigenetic met-
abolic memory from these ani-
mal models of diabetic wound
healing9,30 and free-living
humans7 to include cell culture
studies on human fibroblasts in
the context of diabetic foot
ulceration. Though further con-
firmatory studies are needed,
the decrease in global DNA
methylation observed is similar
to decreases observed in cancer
studies,43 thus supporting clini-
cal significance of our findings.
The most striking finding in
our study was the consistent
DNA methylation pattern iden-
tified in both DFFs and DFUFs when they were compared to
NFFs. Importantly, this identifies a consistent diabetic epigeno-
type of metabolic memory regardless of ulcer status across multi-
ple primary fibroblast cell lines. Our study is novel in that we are
comparing cells derived from non-diabetic patients to cells
derived from diabetic patients with and without ulceration,
whereas previous epigenetic metabolic memory studies have only
compared diabetic to non-diabetic tissue6,9,12,13,30 or hyperglyce-
mia vs. normoglycemia.8,10,11 Whether the metabolic memory
that we have identified in our study directly predisposes diabetic
patients to foot ulceration in response to a wounding insult will
require further study. Previous reports in the literature have dem-
onstrated drifts in DNA methylation patterns over the course of
the aging process44 that could potentially confound their inter-
pretation in clinical studies. However, we identified a consistent
methylation profile despite a range of ages in our patient cohort.
This illustrates that the patient’s diabetic history may be a more
critical determinant in methylation than other factors such as
age. Furthermore, it is possible that the prolonged exposure of
DFUF to a sustained inflammatory environment when compared
to DFF (Table 1) may impact their cellular and molecular phe-
notype. For example, it is known that mouse models of DFU are
typified by a failure to shift from an M1 inflammatory
3A. 3B.
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Figure 3. Genomic context of common diabetic differentially methylation loci. Diabetic methylation localizes to
proximal and distal regulatory regions and within gene bodies. (A). Common diabetic DMPs annotated to gene-
centric and CpG island-centric regions based on the Illumina annotation, to DnaseI hypersensitive sites (DHS),
insulators and enhancer regions through association with ENCODE data.68,69 (B). Co-localization of diabetic
DMPs compared to permutation-generated control sites with histone modiﬁcations in Normal Human Lung
Fibroblasts, derived from the EpiExplorer database. (C). Localization of diabetic DMPs, compared to control sites,
to transcription factor binding sites (TFBS) across all tissues, derived from the EpiExplorer database.
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macrophage to an M2 reparative macrophage responses leading
to poor healing.45-47 This suggests that a longer duration of dia-
betes in DFUF compared to DFF may result in other inflamma-
tory complications that are not unique to diabetes, but rather
are common to other complex diseases such as atherosclerosis.
However, at the level of DNA methylation, our analysis
identifies consistent patterns despite the differing diabetes
duration and exposure to inflammatory conditions between
DFUF and DFF.
The identified metabolic memory epigenetic patterns seen in
fibroblast cell lines derived from diabetic patients are localized to
genes implicated in diabetic pathogenesis and wound healing.19
Functional annotation identified enrichment of gene clusters
implicated in angiogenesis, ECM regulation, and myofibril func-
tion. In addition, the interaction network generated using litera-
ture specific to skin through Ingenuity Pathway Analysis (IPA)
identified interactions with genes that are key regulators of nor-
mal wound healing and are altered in non-healing skin. For
example, Type I collagen and fibronectin play important roles in
the development of a provisional ECM that is essential for nor-
mal wound healing.33 The interaction network identified several
notable nodes, including integrin a 3 and laminin 5, which play
central roles in directing re-epithelialization, and c-myc, which is
associated with a non-healing epithelial phenotype in chronic,
non-healing wounds.32 We identified differential methylation
associated with COL4A1, which is biologically important as this
protein directly interacts with BMPs to modulate TGFb regula-
tion of myofibroblast differentiation required for wound contrac-
tion.48 Differential methylation associated with the pro-
angiogenic cytokine FGF1 may underlie impaired angiogenesis
characteristic of diabetic patients19 and contribute to poor
wound healing outcomes. PLAU is a critical regulator in tissue
remodeling and angiogenesis, with PLAU-deficient mice display-
ing delayed wound healing, decreased keratinocyte migration
required for re-epithelialization, and impaired angiogenesis.49
Table 3 - Functional annotation clustering of diabetic DMPs
Term p value Genes Fold Enrichment
Annotation Cluster #1 – Enrichment Score: 1.45
oxidoreductase 0.004 NOX4, PXDN, AKR1E2, CYP26B1, PDHA2, MOXD1 5.40
GO:0055114»oxidation reduction 0.008 NOX4, PXDN, AKR1E2, CYP26B1, PDHA2, MOXD1 4.54
GO:0020037»heme binding 0.030 NOX4, PXDN, CYP26B1 10.73
GO:0046906»tetrapyrrole binding 0.033 NOX4, PXDN, CYP26B1 10.06
GO:0005506»iron ion binding 0.150 NOX4, PXDN, CYP26B1 4.22
endoplasmic reticulum 0.401 NOX4, CYP26B1, MOXD1 2.13
Annotation Cluster #2 – Enrichment Score: 1.28
GO:0030016»myoﬁbril 0.026 CACNA1C, CACNA1S, VCL 11.52
GO:0044449»contractile ﬁber part 0.027 CACNA1C, CACNA1S, VCL 11.31
GO:0043292»contractile ﬁber 0.031 CACNA1C, CACNA1S, VCL 10.56
disease mutation 0.367 COL4A1, MAN2B1, CACNA1C, CACNA1S, VCL 1.59
Annotation Cluster #3 – Enrichment Score: 1.18
angiogenesis 0.007 COL4A2, COL4A1, FGF1 23.01
GO:0005578»proteinaceous extracellular matrix 0.035 COL4A2, COL4A1, NAV2, FGF1 5.33
GO:0031012»extracellular matrix 0.042 COL4A2, COL4A1, NAV2, FGF1 4.94
GO:0005576»extracellular region 0.074 PXDN, COL4A2, COL4A1, NTF3, NAV2, FCRLA, FGF1, PLAU, VCL 1.91
hsa05200:Pathways in cancer 0.276 COL4A2, COL4A1, FGF1 2.74
GO:0044421»extracellular region part 0.373 COL4A2, COL4A1, NAV2, FGF1 1.78
Differentially methylated diabetic genes are enriched in functions associated with redox reactions, contraction, extracellular matrix and angiogenesis. DAVID
functional annotation clustering of genes associated with diabetic DMPs demonstrates an enrichment of biologically relevant functions within the context
of diabetes and wound healing. p-values of individual annotation terms are generated from a modiﬁed Fisher exact test and cluster enrichment scores are
calculated as the geometric mean of all the enrichment p-values of each annotation term in the group72.
Figure 4. Interaction network of differentially methylated diabetic
genes. Ingenuity Pathway Analysis (IPA) was used to generate an inter-
action network using all the genes in our list and any ﬁrst, second or
third order interactions with other genes based on literature ﬁndings
with speciﬁcity to the dermis, epidermis, and skin. Gray indicates genes
that are differentially methylated in diabetic ﬁbroblasts, while white rep-
resents genes that were not identiﬁed to be differentially methylated
but interact with genes in our list.
www.landesbioscience.com 1345Epigenetics
Taken together, this supports that the identified epigenetic pro-
file includes genes and interactions that are implicated in wound
healing and repair.
Most of our gene specific findings are novel, as they differ
from previous reports investigating genome wide DNA methyla-
tion profiles within the context of diabetes. For example, Hidalgo
et al. identified significant associations between DNA methyla-
tion and clinical markers of diabetes in CD4 cells that were
localized to ABCG1.50 We did not find differential methylation
of ABCG1 in any of our contrasts, suggesting that these findings
are likely to be specific for specific cell and tissue types.40 How-
ever, other studies have identified significant differences in the
KCNQ1 gene, which we found to be differentially methylated in
NFF vs. DFUF contrast, when comparing diabetic to non-dia-
betic subjects in pancreatic b cells,51 in adipose tissue of MZ
twins discordant for type 2 diabetes,52 and in placenta and cord
blood in mothers with gestational diabetes.53
Interpreting genome-wide epigenomic data relies on analyzing
the interdependency of DNA methylation and histone modifica-
tion patterns that cooperatively determine transcriptional activ-
ity.54,55 Previous studies in the context of cancer56 and cell
differentiation57 have identified DNA methylation patterns and
histone modifications that interact to drive gene expression and
functional outcomes. In this study, we have identified the epige-
nomic landscape at the level of DNA methylation and we have
associated this pattern with histone modifications by comparing
them to other fibroblast lines and conserved transcription factor
binding sites (TFBS) to gain insight into these cooperative,
higher levels of epigenomic regulation. Although subject to fur-
ther studies, our analyses suggest that diabetic DNA methylation
patterns co-localize with activating histone modifications and
previously identified TFBSs, suggesting that differentially meth-
ylated regions are highly regulated at multiple levels. Our present
study is limited in that we have do not have corresponding gene
expression analyses; however, we have interpreted the potential
functional effects of our DNA methylation patterns to gene
expression based on localization and anticipate that future studies
will incorporate integrated analyses of histone modifications and
methylation profiles that will inform more directed analyses of
transcriptional activation.
We have presented the first evidence of an epigenetic pattern
of metabolic memory in fibroblasts within the context of DFUs.
By investigating a cohort of multiple cell lines derived from dia-
betic patients and site-matched controls, we have identified com-
mon epigenetic profiles that are consistent across diabetic
patients that reflect the in vivo conditions. This is the case even
when control diabetic cells were sampled from an adjacent site
on the foot. Identification of these DNA methylation patterns in
cell lines derived from diabetic patients after prolonged passage
in normoglycemic conditions demonstrates the presence of a per-
sistent, metabolic memory in these cells. Identification of genes
in our epigenetic profile that are linked to angiogenesis, ECM
production and myofibril contraction indicate that hyperglyce-
mia-driven, metabolic memory is targeting functions critical to
wound healing. Additional studies will be needed to establish if
this epigenetic-related, metabolic memory may predispose
diabetic patients to impaired healing in response to a wound
insult and will lead to identification of novel therapies directed to
these targets.
Research Design and Methods
Collection of patient-derived cell lines
We collected de-identified discarded skin specimens from 21
to 80 year-old subjects who underwent elective foot surgery at
the Foot Center and Vascular Surgery clinic at the Joslin/Beth
Israel Deaconess Medical Center. Specimens were representative
of 3 patient groups: Diabetic Foot Ulcer Fibroblasts (DFUF)
from individuals with an active foot ulcer, Diabetic non-ulcer-
ated Foot Fibroblasts (DFF) from diabetic individuals without a
foot ulcer and Non-diabetic Foot Fibroblasts (NFF) from
healthy, non-diabetic subjects. All groups were matched for age
and gender (Table 1).In addition, the diabetic groups were
matched for duration of diabetes and glycemic control as defin-
ed by the levels of HbA1c. The discarded skin specimens were
collected at the time of the surgical procedure in the operating
room. Only the skin specimens that were determined by the
operating surgeon to be discarded specimens that required no
further evaluation were collected and used for this study. All pro-
cedures were approved by the Beth Israel Deaconess Medical
Center Institutional Review Board (IRB).
Fibroblasts were isolated from patient biopsies as previously
described.58 In brief, biopsies were treated in dispase overnight at
4C and then centrifuged to collect any released cells followed by
removal of the epidermis from the dermis the following day. Sub-
sequently, the dermis was cut into small pieces and added to the
cell pellet, then treated with collagenase and hyalurondiase in
DMEM-F12 (Invitrogen, #11330–057) for one hour at 37C
with stirring. The cell suspension was mixed with red blood cell
lysis buffer for 2 minutes, centrifuged, and then cells were col-
lected and plated with the biopsy pieces on tissue culture plastic.
Fibroblasts were expanded and second passage stocks were frozen
in liquid nitrogen. Fibroblasts were grown in 1g/L glucose
DMEM (Invitrogen, #11885–092), 10% FBS (ThermoScien-
tific, HyClone #SH30071.03), HEPES (Sigma, #4034) and Pen/
Strep/Fung (Invitrogen, #15240–062). Cells were passaged after
reaching confluence. Lines were routinely checked for myco-
plasma contamination with MycoAlert Mycoplasma detection
kin (Lonza #LT07–218, Rockland, ME) and PCR (Sigma,
#MP0025). Flow cytometry analysis was performed to confirm
fibroblast identity (data not shown).
DNA extraction
Cells were collected as cell pellets after 4 passages in normo-
glycemic culture media. DNA was extracted using the Qiagen
DNeasy kit (Qiagen, #S407992) per manufacturer’s instructions.
DNA quality was confirmed by a clean band observed on agarose
gel electrophoresis (data not shown) and 260/280 >1.8 as
measured by Nanodrop.
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LC/MS assay
Global genomic DNA methylation was investigated using the
electrospray ionization LC/MS method as previously described.59
Briefly, 500ng of genomic DNA was digested with nuclease P1
(Sigma-Aldrich #N8630), venom phosphodiesterase I (Sigma-
Aldrich, #P-3243) and alkaline phosphatase (Sigma-Aldrich
#P-4252) to yield individual nucleotides. Isotope labeled [15N3]
2’-deoxycytidine and (methyl-d3, ring-6-d1)-5-methyl-2’-deoxy-
cytidine internal standards were added to the digested DNA,
then samples were run in the electrospray LC/MS. To determine
percent methylation, we first calculated the mass of sample meth-
ylated cytosine by multiplying the ratio of the known mass of the
labeled methylcytosine internal standard (ISmC) to ISmC peak
area by the peak area of the unlabeled methylcytosine. We calcu-
lated the mass of the sample unmethylated cytosine by multiply-
ing the ratio of the known mass of the labeled cytosine internal
standard (ISC) to ISC peak area by the peak area of the unlabeled
cytosine. Percent methylated cytosine was calculated as the mass
of methylated cytosine divided by the sum of the masses of meth-
ylated cytosine plus unmethylated cytosine.
DNA methylation array
The Illumina Infinium HumanMethylation450K BeadChip
array (Illumina, #WG-314–1003) was used to investigate
genome-wide DNA methylation at 485,577 loci across the
genome, covering 99% of RefSeq genes at single-base resolu-
tion.60 The Methylation450K array uses 2 different probe types
with unique chemistries enabling interrogation of both high and
low density CpG regions in the genome. Briefly, high-quality
genomic DNA was sent to the Microarray Facility at the Yale
Center for Genome Analysis (New Haven, CT) and samples were
sodium bisulfite treated, amplified, fragmented, and hybridized to
the array. Subsequently, fluorescently labeled dNTPs were incor-
porated onto the probe through single base extension enabling
determination of the methylation status at the single loci. All pro-
cedures were performed per manufacturer’s instructions.
Statistical Analysis
The Methylation450K array was analyzed using the minfi
package61 through R/Bioconductor.62 Briefly, 2 Illumina IDAT
files per sample were read into RStudio63 with fluorescence data
per probe in Cy3 and Cy5 fluorescence channels. All minfi qual-
ity control analyses were performed, including determining
whether any probes yielded a detection p value >0 .01 in >50 %
of samples. All analyses supported that all arrays were of good
quality and did not require any specific array or subset of probes
to be filtered out due to poor quality. Arrays were normalized
using Subset quantile Within Array Normalization (SWAN)
through minfi, which is a normalization method designed specifi-
cally to address the technical and biological variability in the
Methylation450K arrays due to the type I and type II probes.64
Following normalization, all probes containing SNPs and probes
mapped to sex chromosomes were filtered out to prevent bias
due to unknown genetic background and mixed gender of sam-
ples, respectively, yielding 470,870 probes for subsequent analy-
sis. Beta values per probe were calculated as b D M/(MCUCa),
where M and U are the methylated and unmethylated signals
and a is an arbitrary offset of 100. Three 2-group contrasts were
performed with the data, namely DFUF vs. NFF, DFF vs. NFF,
DFUF vs. DFF. Differentially Methylated Probes (DMPs) in the
2-group contrasts were identified as probes with a b value differ-
ence of > D 0.2 between groups and p < 0.06 in the Mann-
Whitney test. We used p < 0 .06 as our threshold in these analy-
ses because we identified a large number of probes at the p D
0.0596 level and deemed that this to be equivalent to the canoni-
cal threshold of p D 0.05. As we expected to find fewer, more
subtle differences in our biological model compared to previous
cancer epigenomic studies,65 we generated our DMP lists using
an uncorrected p value and then identified similarities in the lists
between contrasts as an additional level of statistical robustness.
One analysis was performed using all 3 groups, defining DMPs
as probes with a b value difference of p > D 0.2 and p < 0 .05
in the Wilcoxon rank sum test. We used the subset of probes
identified from the 3-group analysis for hierarchical clustering
using the Euclidean method. Based on the individual CpG reso-
lution of the Methylation450K array and the findings from Bibi-
kova et al.60 that a b value difference of > D 0.2 can be detected
with 99%, subsequent site-specific validation is outside the scope
of this analysis, similar to other reports using this array in the
literature.66,67
All other statistical analyses were performed in RStudio.63
Two-way ANOVAs by diabetes and ulcer status were used to
analyze LC/MS global DNA methylation.
Bioinformatic Analysis
DMPs were annotated to gene-centric and CpG island-centric
regions using the provided Illumina annotation, enabling associa-
tion of DMPs to 1500 or 200 base pairs upstream of Transcrip-
tion Start Sites (TSS1500, TSS200 respectively), 5’ untranslated
region (5’UTR), first exon, gene body, 3’UTR, CpG island and
north or south CpG island shore or shelf. The genomic region
annotation was expanded by associating DMP locations with
publicly available databases including Regulatory Elements Data-
base68 (http://dnase.genome.duke.edu/) to identify DNase
Hypersensitive Sites (DHSs) and the EpiExplorer69 (http://epi-
explorer.mpi-inf.mpg.de/) database to identify insulators,
enhancers, histone modification patterns and Transcription Fac-
tor Binding Sites (TFBSs). All EpiExplorer analyses compared
our set of DMP-loci with a randomly generated control set of
loci to gain insight into enrichments within our set.69
We used 2 annotation methods to associate DMPs with genes
based on localization. First, DMPs were associated with genes by
using the provided Illumina annotation for probes that fall
within 1500bp upstream of the gene to the 3’UTR. Second, since
it is well documented that methylation sites located far away
from genes can influence gene expression,70 we expanded on our
gene annotation by identifying DMPs that fall within a DHS site
that is associated with changes in expression of genes and subse-
quently associated our DMPs with those genes as has been previ-
ously performed by others.68,71
We explored our list of genes associated with DMPs by using
the functional annotation table and functional annotation
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clustering analyses in DAVID72 with medium stringency param-
eters and by using Ingenuity Pathway Analysis (Ingenuity Sys-
tems, Redwood City, CA) to generate interaction networks based
on literature in dermal and epidermal tissues.
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